News 19.12.2016 Schlieren (Zurich), Switzerland, – Kuros Biosciences Ltd. (SIX:KURN) (“Kuros”) today announced the signing of a combination agreement with Xpand Biotechnology B.V. (“Xpand”) with the intention to acquire Xpand by way of an exchange of all Xpand shares for up to 2.105 million new Kuros shares, subject to customary conditions. Xpand...
News 07.12.2016 Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in Schlieren/Zurich, Switzerland. AL-S Pharma will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that...
External events 28.10.2016 Please find the link to the SECA event calendar below. SECA members and non-members are invited. (more…)
External events 28.10.2016 Event calendar of the Technoparks Zurich, Winterthur, Aargau, Luzern and Ticino. (more…)
Internal events
Event date: 23.01.2018
Krebs Cycle reprogrammed for Cytokines
Luke O`Neill,
Trinity College Dublin
11:30 a.m., seminar room, 4th floor, Wagistrasse 12
Luke O`Neill is professor of Biochemistry and Immunology at Trinity College in Dublin, Ireland. His research investigates molecular pathways of inflammation, in particular innate immune mechanisms. His work on activation and signaling pathways of toll-like receptors...